Royalty Pharma (RPRX) Enterprise Value (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Enterprise Value data on file, last reported at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 21.99% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (up 21.99% YoY), and the FY2025 full-year result was $2.6 billion, up 7.97% from the prior year.
• Enterprise Value declined to $2.4 billion in Q1 2026, from $2.6 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $3.1 billion in Q4 2023 to a low of $1.4 billion in Q2 2023.
• A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 44.83% in 2022 and soared 70.46% in 2025, its largest moves.
• Tracing RPRX's Enterprise Value over 5 years: stood at $2.2 billion in 2022, then jumped by 41.65% to $3.1 billion in 2023, then dropped by 21.35% to $2.4 billion in 2024, then gained by 7.97% to $2.6 billion in 2025, then retreated by 6.17% to $2.4 billion in 2026.
• Business Quant data shows RPRX's Enterprise Value at $2.4 billion in Q1 2026, $2.6 billion in Q4 2025, and $2.3 billion in Q3 2025.